ETFs positioned on Bristol-Myers Squibb Company

Name Weight AuM 1st Jan change Investor Rating
12.97% 380 M€ +10.16% -
4.99% 2 M€ -.--%
4.01% 20 M€ +16.38% -
2.63% 31 M€ +32.45% -
2.37% 2 M€ -25.75%
2.08% 9 M€ -.--% -
1.90% 16 M€ -3.37%
1.85% 2 M€ -.--%
1.43% 5 M€ -72.95% -
1.42% 9 M€ -4.31% -
1.37% 26 M€ +16.85% -
1.26% 752 M€ +13.25%
1.00% 83 M€ +19.73%
0.99% 11 M€ +19.99%
0.97% 36 M€ +17.68% -
0.97% 412 M€ +15.33% -
0.83% 115 M€ +26.18%
0.82% 7 M€ +12.54%
0.80% 2,795 M€ +17.41%
0.78% 3 M€ +15.16% -
0.78% 4 M€ -.--% -
0.78% 13 M€ -.--% -
Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Employees
34,100
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
surperformance-ratings-light-chart BRISTOL-MYERS-SQUIBB-COMPMore Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
56.28USD
Average target price
60.58USD
Spread / Average Target
+7.64%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. BMY Stock
  4. ETFs Bristol-Myers Squibb Company